U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07198854) titled 'Advantaged ACLF Patients for MSCs Treatment' on Sept. 22.
Brief Summary: Mesenchymal stromal cells (MSCs) are potential therapy for many diseases, with the ability of tissue regeneration, repair and immunomodulation. Acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. Previous studies showed that MSCs can improve the outcomes of Hepatitis B virus (HBV)-related ACLF patients. However, there are still some ACLF patients who have not benefited from MSC treatment. Thus, identifying advantaged population of ACLF patients received MSCs therapy is of great significance for promotion of MSCs therapy.
This retrospe...